Канал: Informative

KRAS downregulates FAS (death cell receptor) expression on pancreatic cancer cells #Code: 724

KRAS downregulates FAS (death cell receptor) expression on pancreatic cancer cells #Code: 724

Effect KRAS mutation on the T-cells and myeloid cells #Code: 723

Effect KRAS mutation on the T-cells and myeloid cells #Code: 723

Eradication of pancreatic tumors after elimination of KRAS mutation #Code: 722

Eradication of pancreatic tumors after elimination of KRAS mutation #Code: 722

Effect of RMC-7977 on native models of Pancreatic cancer (PDAC) #Code: 721

Effect of RMC-7977 on native models of Pancreatic cancer (PDAC) #Code: 721

RMC-7977 selectivity towards the tumours #Code: 720

RMC-7977 selectivity towards the tumours #Code: 720

Pharmacology of RAS dependence of RMC-7977 #Code: 719

Pharmacology of RAS dependence of RMC-7977 #Code: 719

RMC-7977 exhibits anti-tumor activity against Pancreatic cancer (PDAC) in-vivo #Code: 718

RMC-7977 exhibits anti-tumor activity against Pancreatic cancer (PDAC) in-vivo #Code: 718

RMC-7977 (Ras-inhibitor) exhibits anti-tumor activity against Pancreatic cancer (PDAC) #Code: 717

RMC-7977 (Ras-inhibitor) exhibits anti-tumor activity against Pancreatic cancer (PDAC) #Code: 717

Overview of enhanced CAR T-cell Immunotherapy against solid malignancy (Ovarian Cancer) #Code: 716

Overview of enhanced CAR T-cell Immunotherapy against solid malignancy (Ovarian Cancer) #Code: 716

Improved efficiency of CAR T-cell Immunotherapy against solid malignancy (Ovarian Cancer) #Code: 715

Improved efficiency of CAR T-cell Immunotherapy against solid malignancy (Ovarian Cancer) #Code: 715

TAGLN2 helps in T cell metabolic fitness #Code: 714

TAGLN2 helps in T cell metabolic fitness #Code: 714

ER stress (XBP1s) cause low expression of TAGLN2 on cell surface of CD8+T-cells #Code: 713

ER stress (XBP1s) cause low expression of TAGLN2 on cell surface of CD8+T-cells #Code: 713

TAGLN2 assists FABP5 in activated CD8+Tcells for lipid uptake in ovarian cancer condition #Code: 712

TAGLN2 assists FABP5 in activated CD8+Tcells for lipid uptake in ovarian cancer condition #Code: 712

Ovarian Cancer disrupts CD8+T (CAR-T) cell's via downregulating FABP5 surface expression #Code: 711

Ovarian Cancer disrupts CD8+T (CAR-T) cell's via downregulating FABP5 surface expression #Code: 711

DANA effect on Calcium oscillation, sialic acid & comparison with sialidase isoenzyme Neu3 #Code:710

DANA effect on Calcium oscillation, sialic acid & comparison with sialidase isoenzyme Neu3 #Code:710

DANA effect on Blood Glucose and Plasma insulin levels in-vivo in the absence of glucose #Code: 709

DANA effect on Blood Glucose and Plasma insulin levels in-vivo in the absence of glucose #Code: 709

Blood Glucose and Plasma insulin levels are affected by DANA #Code: 708

Blood Glucose and Plasma insulin levels are affected by DANA #Code: 708

DANA, a sialidase inhibitor, could be potential anti-diabetic treatment #Code: 707

DANA, a sialidase inhibitor, could be potential anti-diabetic treatment #Code: 707

DiaBZl stimulates NY-ESO-1 antigen expression in-vivo #Code: 706

DiaBZl stimulates NY-ESO-1 antigen expression in-vivo #Code: 706

STING agonist DiaBZl along with engineered T cells impairs tumor growth #Code: 705

STING agonist DiaBZl along with engineered T cells impairs tumor growth #Code: 705

DiaBZl stimulates NY-ESO-1 antigen expression on tumor cells #Code: 704

DiaBZl stimulates NY-ESO-1 antigen expression on tumor cells #Code: 704

DiaBZl stimulates tumor Apoptosis #Code: 703

DiaBZl stimulates tumor Apoptosis #Code: 703

DiaBZl stimulates TCR signaling in High Affinity engineered T cells (HATs) #Code: 702

DiaBZl stimulates TCR signaling in High Affinity engineered T cells (HATs) #Code: 702

DiaBZl stimulates sting signaling pathways in High Affinity engineered T cells (HATs) #Code: 701

DiaBZl stimulates sting signaling pathways in High Affinity engineered T cells (HATs) #Code: 701

Effects of DiaBZl on T-cell engineered with IG4HA-T on cytotoxicity against tumor cells #Code: 700

Effects of DiaBZl on T-cell engineered with IG4HA-T on cytotoxicity against tumor cells #Code: 700

DiaBZl increases T-cell cytotoxicity against tumor cells by STING #Code: 699

DiaBZl increases T-cell cytotoxicity against tumor cells by STING #Code: 699

sTRA & CA19-9 helps in predicting the time to progress (TTP) of PDAC #Code: 698

sTRA & CA19-9 helps in predicting the time to progress (TTP) of PDAC #Code: 698

sTRA & CA19-9 dual expression on PDAC often represent Secretory epithelia & vice-versa #Code: 697

sTRA & CA19-9 dual expression on PDAC often represent Secretory epithelia & vice-versa #Code: 697

sTRA & CA19-9 glycans express on cultured pancreatic cancer cells #Code: 696

sTRA & CA19-9 glycans express on cultured pancreatic cancer cells #Code: 696

sTRA & CA19-9 glycans express non-identical subset of pancreatic cancer cell populations #Code: 695

sTRA & CA19-9 glycans express non-identical subset of pancreatic cancer cell populations #Code: 695

sTRA glycans express independent of CA19-9 glycans on pancreatic cancer (PDAC) #Code: 694

sTRA glycans express independent of CA19-9 glycans on pancreatic cancer (PDAC) #Code: 694

sTRA glycan could be the potential biomarker for pancreatic cancer apart from CA19-9 #Code: 693

sTRA glycan could be the potential biomarker for pancreatic cancer apart from CA19-9 #Code: 693

B4ST6FC (Glycosyltransferase engineered antibody) has better therapeutic results on mice #Code: 692

B4ST6FC (Glycosyltransferase engineered antibody) has better therapeutic results on mice #Code: 692

Role of platelets in in-vivo sialylation #Code: 691

Role of platelets in in-vivo sialylation #Code: 691

Site-specific sialylation of B4ST6FC results in antiinflammation response #Code: 690

Site-specific sialylation of B4ST6FC results in antiinflammation response #Code: 690

Enzyme activity (sialyltransferase) responsible for reduced inflammation #Code: 689

Enzyme activity (sialyltransferase) responsible for reduced inflammation #Code: 689

In-vivo sialylation to suppress inflammation #Code: 688

In-vivo sialylation to suppress inflammation #Code: 688

In-vivo validation of Anti-inflammatory function of engineered antibody #Code: 687

In-vivo validation of Anti-inflammatory function of engineered antibody #Code: 687

Anti-inflammatory antibody using engineered glycosyltransferases #Code: 686

Anti-inflammatory antibody using engineered glycosyltransferases #Code: 686

Pancreatic Cancer cells drug response in ex-vivo models #Code: 685

Pancreatic Cancer cells drug response in ex-vivo models #Code: 685

In-vivo and Ex-vivo PDAC matrisome analysis #Code: 684

In-vivo and Ex-vivo PDAC matrisome analysis #Code: 684

Matrisome Recapitulation in Ex-vivo models on PDAC #Code: 683

Matrisome Recapitulation in Ex-vivo models on PDAC #Code: 683

Tunability of PA-ECM in-vitro hydrogel towards PDAC cultures #Code: 682

Tunability of PA-ECM in-vitro hydrogel towards PDAC cultures #Code: 682

Different ex-vivo model comparisons towards PDAC in-vivo behavior #Code: 681

Different ex-vivo model comparisons towards PDAC in-vivo behavior #Code: 681

Transcriptome analysis to compare ex-vivo models with human pancreatic cancer tissue #Code: 680

Transcriptome analysis to compare ex-vivo models with human pancreatic cancer tissue #Code: 680

Validating the custom design PA-ECM: 3D invitro model to replicate in vivo PDAC behaviour #Code: 679

Validating the custom design PA-ECM: 3D invitro model to replicate in vivo PDAC behaviour #Code: 679

Characterization & design of PA-ECM: 3D invitro model to replicate in vivo PDAC behaviour #Code: 678

Characterization & design of PA-ECM: 3D invitro model to replicate in vivo PDAC behaviour #Code: 678

Stiffness mediated chemoresistance in PDAC #Code: 677

Stiffness mediated chemoresistance in PDAC #Code: 677

HA-CD44 interactions in high HELP mediates chemoresistance in PDAC #Code: 676

HA-CD44 interactions in high HELP mediates chemoresistance in PDAC #Code: 676

HA in high HELP mediates chemoresistance in PDAC #Code: 675

HA in high HELP mediates chemoresistance in PDAC #Code: 675

Drug efflux transporter (ABCG2) mediates chemoresistance in PDAC #Code: 674

Drug efflux transporter (ABCG2) mediates chemoresistance in PDAC #Code: 674

Long-term effect of stiff matrix to chemoresistance in pancreatic tumor #Code: 673

Long-term effect of stiff matrix to chemoresistance in pancreatic tumor #Code: 673

Tumor-matrix (Extra-cellular matrix) contributes to chemoresistance in pancreatic tumor #Code: 672

Tumor-matrix (Extra-cellular matrix) contributes to chemoresistance in pancreatic tumor #Code: 672

Clinical Relevance of VCAM-1 and CCL18 on Pancreatic Cancer (PDAC) prognosis #Code: 671

Clinical Relevance of VCAM-1 and CCL18 on Pancreatic Cancer (PDAC) prognosis #Code: 671

VCAM-1 helps in proliferation of the Pancreatic Cancer (PDAC) #Code: 670

VCAM-1 helps in proliferation of the Pancreatic Cancer (PDAC) #Code: 670

Lactate mediates polarization of the macrophages (in-vitro) #Code: 669

Lactate mediates polarization of the macrophages (in-vitro) #Code: 669

VCAM-1 modulates Warburg effect of PDAC cells in vitro #Code: 668

VCAM-1 modulates Warburg effect of PDAC cells in vitro #Code: 668

VCAM-1 modulates migration and invasion of PDAC #Code: 667

VCAM-1 modulates migration and invasion of PDAC #Code: 667

VCAM-1 mediates proliferation & cell cycle checkpoint at G1-S in Pancreatic Cancer cells #Code: 666

VCAM-1 mediates proliferation & cell cycle checkpoint at G1-S in Pancreatic Cancer cells #Code: 666

VCAM-1 overexpressed in PDAC patients and PDAC cell lines #Code: 665

VCAM-1 overexpressed in PDAC patients and PDAC cell lines #Code: 665

Characterization of mRNA expression profile between PANC-1 & PANC-1 Coculture with TAM #Code: 664

GW combined with Anti-CD47 suppress PDAC metastasis and progression #Code: 663

GW combined with Anti-CD47 suppress PDAC metastasis and progression #Code: 663

Macrophages extracellular traps (METs) promote activation of CXCL8 (monomer) #Code: 662

Macrophages extracellular traps (METs) promote activation of CXCL8 (monomer) #Code: 662

Macrophages extracellular traps (METs) promote metastasis in PDAC cells by CXCR pathway #Code: 661

Macrophages extracellular traps (METs) promote metastasis in PDAC cells by CXCR pathway #Code: 661

MLKL-driven necroptosis promotes macrophages extracellular traps (METs) #Code: 660

MLKL-driven necroptosis promotes macrophages extracellular traps (METs) #Code: 660

M1 Macrophages helps tumor cells from phagocytosis #Code: 659

M1 Macrophages helps tumor cells from phagocytosis #Code: 659

Crosstalk between M1-macrophages and Cancer cells #Code: 658

Crosstalk between M1-macrophages and Cancer cells #Code: 658

MLKL driven necroptosis promotes metastasis of PDAC in liver accompanied by macrophages #Code: 657

MLKL driven necroptosis promotes metastasis of PDAC in liver accompanied by macrophages #Code: 657

Necroptosis is mediated by upregulation of the MLKL gene & is not dependent on RIPK3 gene #Code: 656

Necroptosis is mediated by upregulation of the MLKL gene & is not dependent on RIPK3 gene #Code: 656

MLKL elevation in PDAC reduced metastasis in liver #Code: 655

MLKL elevation in PDAC reduced metastasis in liver #Code: 655

Roflumilast attenuated STK11 mutated migration in pancreatic cancer (PDAC) #Code: 654

Roflumilast attenuated STK11 mutated migration in pancreatic cancer (PDAC) #Code: 654

STK11 knockout disrupts phosphodiesterases (PDEs) in pancreatic cancer cells #Code: 653

STK11 knockout disrupts phosphodiesterases (PDEs) in pancreatic cancer cells #Code: 653

STK11 knockout in PDAC aggravated metastasis in Liver #Code: 652

STK11 knockout in PDAC aggravated metastasis in Liver #Code: 652

Chicken CAM Xenograft Assay shows STK11 knockout PDAC have increased migration #Code: 651

Chicken CAM Xenograft Assay shows STK11 knockout PDAC have increased migration #Code: 651

STK11 knockout cells have more migration characteristics over control PDAC cells #Code: 650

STK11 knockout cells have more migration characteristics over control PDAC cells #Code: 650

Murine Genes contribution towards migration of pancreatic Cancer #Code: 649

Murine Genes contribution towards migration of pancreatic Cancer #Code: 649

Clinical data suggests high CD44 or SLC16A1 is a prognostic marker fo pancreatic cancer #Code: 648

Clinical data suggests high CD44 or SLC16A1 is a prognostic marker fo pancreatic cancer #Code: 648

Glycolysis regulates the anchorage-independent growth and invasion characteristics #Code: 647

Glycolysis regulates the anchorage-independent growth and invasion characteristics #Code: 647

CD44 and CD24 associated with anchorage-independent growth and invasion characteristics #Code: 646

CD44 and CD24 associated with anchorage-independent growth and invasion characteristics #Code: 646

Metabolic reprogramming of double fluorescence cells (PDAC+ macrophages) #Code: 645

Metabolic reprogramming of double fluorescence cells (PDAC+ macrophages) #Code: 645

Increased Anchorage in pancreatic cancer cells causes increased growth rate/invasiveness #Code: 644

Increased Anchorage in pancreatic cancer cells causes increased growth rate/invasiveness #Code: 644

Intracellular transfer between Macrophages and Pancreatic Cancer cells #Code: 643

Intracellular transfer between Macrophages and Pancreatic Cancer cells #Code: 643

In-vivo Study to validate IRF-7 role in lipid metabolism in Pancreatic cancer(PDAC) #Code: 642

In-vivo Study to validate IRF-7 role in lipid metabolism in Pancreatic cancer(PDAC) #Code: 642

RPS18 in macrophages upregulates ILF3 gene in PDAC, block apoptosis & helps in migration #Code: 641

RPS18 in macrophages upregulates ILF3 gene in PDAC, block apoptosis & helps in migration #Code: 641

IRF7 Gene in M1 type Macrophage upregulates ILF3 gene in Pancreatic Cancer(PDAC) #Code: 640

IRF7 Gene in M1 type Macrophage upregulates ILF3 gene in Pancreatic Cancer(PDAC) #Code: 640

IRF7 Gene in M1 type Macrophage modulates pancreatic cancer biological functions #Code: 639

IRF7 Gene in M1 type Macrophage modulates pancreatic cancer biological functions #Code: 639

IRF7 Gene in M1 type Macrophage modulates pancreatic cancer cellular changes in signaling #Code: 638

IRF7 Gene in M1 type Macrophage modulates pancreatic cancer cellular changes in signaling #Code: 638

Spatial Transcriptome and scRNA reveals cell cell interaction on pancreatic TME #Code: 637

Spatial Transcriptome and scRNA reveals cell cell interaction on pancreatic TME #Code: 637

M2- type- Macrophages help in lipid metabolism in pancreatic cancer cells #Code: 636

M2- type- Macrophages help in lipid metabolism in pancreatic cancer cells #Code: 636

Characterization of PDAC tissue and its comparison with healthy tissue using sc-RNA seq #Code: 635

Characterization of PDAC tissue and its comparison with healthy tissue using sc-RNA seq #Code: 635

Disruption in intercellular transport could disrupt pancreatic cancer cells #Code: 634

Disruption in intercellular transport could disrupt pancreatic cancer cells #Code: 634

Obesity leads to nutrient excess environment that could cause ER stress #Code: 633

Obesity leads to nutrient excess environment that could cause ER stress #Code: 633

Calreticulin on the cell surface helps in the maturation of the dendritic cells #Code: 632

Calreticulin on the cell surface helps in the maturation of the dendritic cells #Code: 632

Calreticulin on cell surface could boost immune response(CD8+T cells) in oxidative stress #Code: 631

Calreticulin on cell surface could boost immune response(CD8+T cells) in oxidative stress #Code: 631

PERK pathway help in translocation of calreticulin on cell surface under oxidative stress #Code: 630

PERK pathway help in translocation of calreticulin on cell surface under oxidative stress #Code: 630

PERK pathways might play a role towards translocation of calreticulin on cell surface #Code: 629

PERK pathways might play a role towards translocation of calreticulin on cell surface #Code: 629

Overexpressed Calreticulin translocated on the cell membrane under oxidative stress #Code: 628

Overexpressed Calreticulin translocated on the cell membrane under oxidative stress #Code: 628

Calreticulin overexpression is correlated with oxidative stress #Code: 627

Calreticulin overexpression is correlated with oxidative stress #Code: 627

Calreticulin can migrate to cell surface on melanocyte apoptosis #Code: 626

Calreticulin can migrate to cell surface on melanocyte apoptosis #Code: 626

Non-functional GPI-APs in CANX-CALR KO, can be rescued with increased ER retention #Code: 625

Non-functional GPI-APs in CANX-CALR KO, can be rescued with increased ER retention #Code: 625

Acetylated and misfolded GPI-APs expressed on the cell surface of CANX-CALR dual knockout #Code: 624

Acetylated and misfolded GPI-APs expressed on the cell surface of CANX-CALR dual knockout #Code: 624

Calnexin and calreticulin mediate Endoplasmic reticulum (ER) quality control #Code: 623

Calnexin and calreticulin mediate Endoplasmic reticulum (ER) quality control #Code: 623

Glycan interaction of Calnexin is required for GPI-APs proper folding/deacylation #Code: 622

Glycan interaction of Calnexin is required for GPI-APs proper folding/deacylation #Code: 622

Non-Glycosylated GPI-APs has calnexin independent mechanism for deacylation #Code: 621

Non-Glycosylated GPI-APs has calnexin independent mechanism for deacylation #Code: 621

Mature GPI-APs expressed on the cell surface of WT and to some extent on CANX-CALR KO #Code: 620

Mature GPI-APs expressed on the cell surface of WT and to some extent on CANX-CALR KO #Code: 620

Calnexin helps in maturation of GPI-APs(glycosylphosphatidylinositol-anchored proteins) #Code: 619

Calnexin helps in maturation of GPI-APs(glycosylphosphatidylinositol-anchored proteins) #Code: 619

TrKB ER-Phagy is mediated by calnexin and Fam134b complex formation #Code: 618

TrKB ER-Phagy is mediated by calnexin and Fam134b complex formation #Code: 618

Calnexin depletion impairs lysosomal turnover of TrKB #Code: 617

Calnexin depletion impairs lysosomal turnover of TrKB #Code: 617

Calnexin phosphorylation at S563 plays crucial role in transport of TrkB to cell surface #Code: 616

Calnexin phosphorylation at S563 plays crucial role in transport of TrkB to cell surface #Code: 616

Calnexin helps in the transport of the TrkB from ER to cell surface #Code: 615

Calnexin helps in the transport of the TrkB from ER to cell surface #Code: 615

Calnexin regulates activation of TrkB #Code: 614

Calnexin regulates activation of TrkB #Code: 614

Calnexin helps in the cerebral cortex development #Code: 613

Calnexin helps in the cerebral cortex development #Code: 613

Calnexin helps in the cerebral cortex development #Code: 612

Calnexin helps in the cerebral cortex development #Code: 612

Acetyl-COA helps acetylation of SMAD3 proteins, resulting it's translocation to nucleus #Code: 611

Acetyl-COA helps acetylation of SMAD3 proteins, resulting it's translocation to nucleus #Code: 611

Acetyl-COA plays an critical role in Fatty Acid oxidation (FAO) and HESCs differentiation #Code: 610

Acetyl-COA plays an critical role in Fatty Acid oxidation (FAO) and HESCs differentiation #Code: 610

CPT2 Gene in Fatty acid oxidation (FAO) pathway is Critical for HESCs differentiation #Code: 609

CPT2 Gene in Fatty acid oxidation (FAO) pathway is Critical for HESCs differentiation #Code: 609

Decreased Fatty acid oxidation (FAO) suppress Embryonic Stem Cells (ESCs) differentiation #Code: 608

Decreased Fatty acid oxidation (FAO) suppress Embryonic Stem Cells (ESCs) differentiation #Code: 608

Decreased Fatty acid synthesis (FAS) enhances Embryonic Stem Cells (ESCs) differentiation #Code: 607

Decreased Fatty acid synthesis (FAS) enhances Embryonic Stem Cells (ESCs) differentiation #Code: 607

FAS and FAO pathway analysis in Embryonic stem cells and Definitive Endoderm #Code: 606

FAS and FAO pathway analysis in Embryonic stem cells and Definitive Endoderm #Code: 606

Embryonic developments of the organs #Code: 605

Embryonic developments of the organs #Code: 605

Pancreatic Cancer: KRAS mutation and FAS receptor correlations in pancreatic cancer #Code: 604

Pancreatic Cancer: KRAS mutation and FAS receptor correlations in pancreatic cancer #Code: 604

Pancreatic Cancer: CD8+ T cells interact with FAS receptor to trigger apoptosis #Code: 603

Pancreatic Cancer: CD8+ T cells interact with FAS receptor to trigger apoptosis #Code: 603

Pancreatic Cancer: Suppresion of FAS receptor (death receptor) reinstates tumor growth #Code: 602

Pancreatic Cancer: Suppresion of FAS receptor (death receptor) reinstates tumor growth #Code: 602

Pancreatic Cancer: KRAS mutations modulates FAS receptor (death receptor) #Code: 601

Pancreatic Cancer: KRAS mutations modulates FAS receptor (death receptor) #Code: 601

Pancreatic Cancer: KRAS mutations lead the Pancreatic adenocarcinoma (PDAC) migration #Code: 600

Pancreatic Cancer: KRAS mutations lead the Pancreatic adenocarcinoma (PDAC) migration #Code: 600

Elimination of KRAS mutation help Immune System to trigger apoptosis Pancreatic Cancer #Code: 599

Elimination of KRAS mutation help Immune System to trigger apoptosis Pancreatic Cancer #Code: 599

Immune Cells Migration to the Cancer and its shortcoming #Code: 598

Immune Cells Migration to the Cancer and its shortcoming #Code: 598

Pathogenesis of Chronic Pancreatitis #Code: 597

Pathogenesis of Chronic Pancreatitis #Code: 597

Chronic Pancreatitis: Regular Intake of Alcohol or Tobacco could lead to malnutrition #Code: 596

Chronic Pancreatitis: Regular Intake of Alcohol or Tobacco could lead to malnutrition #Code: 596

Why pancreatic cancer has a poor prognosis? #Code: 595

Why pancreatic cancer has a poor prognosis? #Code: 595

How KRAS mutation help Pancreatic Cancer cell development? #Code: 594

How KRAS mutation help Pancreatic Cancer cell development? #Code: 594

Immune system response against non-self epitope #Code: 593

Immune system response against non-self epitope #Code: 593

Indirect and Direct Mechanosensing #Code: 592

Indirect and Direct Mechanosensing #Code: 592

Pancreatic Cancer: Chemoresistance & Gemcitabine Intracellular Reprogramming in Tumor #Code: 591

Pancreatic Cancer: Chemoresistance & Gemcitabine Intracellular Reprogramming in Tumor #Code: 591

Anti-Cancer Strategies targeting platelets cancer interactions #Code: 590

Anti-Cancer Strategies targeting platelets cancer interactions #Code: 590

Insights about the platelets role in Cancer Metastasis #Code: 589

Insights about the platelets role in Cancer Metastasis #Code: 589

Role of platelets in Cancer Metastasis #Code: 588

Role of platelets in Cancer Metastasis #Code: 588

Therapeutic Approach to reduce HIV Infectivity using CRISPR #Code: 587

Therapeutic Approach to reduce HIV Infectivity using CRISPR #Code: 587

Pancreatic Cancer: Onset, Early detection and Therapeutic Targets #Code: 586

Pancreatic Cancer: Onset, Early detection and Therapeutic Targets #Code: 586

Nanodrug-bacteria conjugate could help in diagnosing pancreatic cancer #Code: 585

Nanodrug-bacteria conjugate could help in diagnosing pancreatic cancer #Code: 585

Pancreatic Cancer (PCC) & Pancreatic Stellate Cells Interpaly in Tumor Progression #Code: 584

Pancreatic Cancer (PCC) & Pancreatic Stellate Cells Interpaly in Tumor Progression #Code: 584

Glycocalyx role in cancer progression #Code: 583

Glycocalyx role in cancer progression #Code: 583

Skin Cancer, Pathogenesis and possible therapeutic targets #Code: 582

Skin Cancer, Pathogenesis and possible therapeutic targets #Code: 582

Prostrate Cancer Metastasis #Code: 581

Prostrate Cancer Metastasis #Code: 581

Melanoma/Skin Cancer Post Translational Modification Dysregulation #Code: 580

Melanoma/Skin Cancer Post Translational Modification Dysregulation #Code: 580

ECM Remodelling in Cancer Cells #Code: 579

ECM Remodelling in Cancer Cells #Code: 579

Exercise effects on Intracellular signaling during the regenerative process #Code: 578

Exercise effects on Intracellular signaling during the regenerative process #Code: 578

Fatty acid consumption during endurance exercise #Code: 577

Fatty acid consumption during endurance exercise #Code: 577

Fibrotic disease and Possible therapeutic Targets #Code: 576

Fibrotic disease and Possible therapeutic Targets #Code: 576

Intracellular changes: Prolonged Exercise, Low protein diet #Code: 575

Intracellular changes: Prolonged Exercise, Low protein diet #Code: 575

Intracellular changes: Prolonged Exercise, Resistance Exercise & Endurance Training #Code: 574

Intracellular changes: Prolonged Exercise, Resistance Exercise & Endurance Training #Code: 574

Immune Cells: Intracellular signaling when Immune Cells (B-cells & T-cells) with antigen #Code: 573

Immune Cells: Intracellular signaling when Immune Cells (B-cells & T-cells) with antigen #Code: 573

Immune cells: T-cell differentiation into (T helper cells) Th1 and Th2 cells #Code: 572

Immune cells: T-cell differentiation into (T helper cells) Th1 and Th2 cells #Code: 572

Pancreatic Cancer: Reprogramming in PDAC & Role of TME in altered metabolism in PDAC #Code: 571

Pancreatic Cancer: Reprogramming in PDAC & Role of TME in altered metabolism in PDAC #Code: 571

Congenital disorder of Glycosylation (CDG) - Diseases #Code: 570

Congenital disorder of Glycosylation (CDG) - Diseases #Code: 570

Glimpse of Aberrant Glycosylation in cancer cells. Part-2 #Code: 569

Glimpse of Aberrant Glycosylation in cancer cells. Part-2 #Code: 569

Glimpse of Aberrant Glycosylation in cancer cells. Part-1 #Code: 568

Glimpse of Aberrant Glycosylation in cancer cells. Part-1 #Code: 568

Hedgehog signaling pathway (Cancer exploit the growth pathway for their own benefit) #Code: 567

Hedgehog signaling pathway (Cancer exploit the growth pathway for their own benefit) #Code: 567

Type 2 Diabetes Possible Treatment #Code: 566

Type 2 Diabetes Possible Treatment #Code: 566

Therapeutic targets for tumor microenvironment (TME) of Pancreatic cancer (PDAC) #Code: 565

Therapeutic targets for tumor microenvironment (TME) of Pancreatic cancer (PDAC) #Code: 565

Dichotomy of stroma towards pancreatic cancer (PDAC) #Code: 564

Dichotomy of stroma towards pancreatic cancer (PDAC) #Code: 564

Cell experience mechanics from ECM (Extra cellular matrix) #Code: 563

Cell experience mechanics from ECM (Extra cellular matrix) #Code: 563

Glycans contribution in cancer hallmarks and some glycans based therapeutic approaches #Code: 562

Glycans contribution in cancer hallmarks and some glycans based therapeutic approaches #Code: 562

Role of Post Translational modification on Cancer hallmarks #Code: 561

Role of Post Translational modification on Cancer hallmarks #Code: 561

Intermittent fasting in Type-I diabetic patients alleviates cognitive dysfunction #Code: 560

Intermittent fasting in Type-I diabetic patients alleviates cognitive dysfunction #Code: 560

Autophagy and Starvation #Code: 559

Autophagy and Starvation #Code: 559

UFM1 Conjugation pathway and its role in proteostasis #Code: 558

UFM1 Conjugation pathway and its role in proteostasis #Code: 558

UFMylation and its role in Regulating Cell fate #Code: 557

UFMylation and its role in Regulating Cell fate #Code: 557

Perineural Invasion in pancreatic ductal adenocarcinoma (PDAC) #Code: 556

Perineural Invasion in pancreatic ductal adenocarcinoma (PDAC) #Code: 556

Regulatory network of tumor invasion and metastasis #Code: 555

Regulatory network of tumor invasion and metastasis #Code: 555

Targeting ECM stiffness along with Immunotherapy might improve cancer Diagonsis #Code: 554

Targeting ECM stiffness along with Immunotherapy might improve cancer Diagonsis #Code: 554

Immune Response & Cancer Cells intracellular signaling pathway modulate by ECM stiffness #Code: 553

Immune Response & Cancer Cells intracellular signaling pathway modulate by ECM stiffness #Code: 553

Mechanical forces influence on Immune Response #Code: 552

Mechanical forces influence on Immune Response #Code: 552

Cancer phenotype and Extra cellular Matrix (ECM) Stiffness #Code: 551

Cancer phenotype and Extra cellular Matrix (ECM) Stiffness #Code: 551

Cell Polarity affect Cancer Initiation #Code: 550

Cell Polarity affect Cancer Initiation #Code: 550

Glycocalyx composition affect cancer progresssion #Code: 549

Glycocalyx composition affect cancer progresssion #Code: 549

Glycosylation in Gliomas (Brain Cancer) #Code: 548

Glycosylation in Gliomas (Brain Cancer) #Code: 548

High Spatial Resolution Multi-Omics Sequencing using Deterministic Barcoding (DBiT) #Code: 547

High Spatial Resolution Multi-Omics Sequencing using Deterministic Barcoding (DBiT) #Code: 547

ECM-dependent mechanotransduction modulates cellular behaviour #Code: 546

ECM-dependent mechanotransduction modulates cellular behaviour #Code: 546

Mechanotransduction changes in the pancreatic cancer cells promotes metastasis #Code: 545

Mechanotransduction changes in the pancreatic cancer cells promotes metastasis #Code: 545

Parkinson Disease Pathogenesis #Code: 544

Parkinson Disease Pathogenesis #Code: 544

Amyotrophic Lateral Sclerosis (ALS) Pathological mechanism (Neurodegenerative disease) #Code: 543

Amyotrophic Lateral Sclerosis (ALS) Pathological mechanism (Neurodegenerative disease) #Code: 543

Mechanosensing triggers biochemical changes in Huntington's disease #Code: 542

Mechanosensing triggers biochemical changes in Huntington's disease #Code: 542

Mechanotransduction using biochemical pathways in Alzheimer's Disease #Code: 541

Mechanotransduction using biochemical pathways in Alzheimer's Disease #Code: 541

Platelets and TPO (thrombopoietin) cytokines feedback loop #Code: 540

Platelets and TPO (thrombopoietin) cytokines feedback loop #Code: 540

Healthy Pancreas and Pancreatic Cancer #Code: 539

Healthy Pancreas and Pancreatic Cancer #Code: 539

Cell Proliferation and Death Receptor #Code: 538

Cell Proliferation and Death Receptor #Code: 538

Adeno Vector Vaccine and its Transduction Pathways #Code: 537

Adeno Vector Vaccine and its Transduction Pathways #Code: 537

How Vaccine helps in generating antibodies against the virus (Adeno Associated Vector) #Code: 536

How Vaccine helps in generating antibodies against the virus (Adeno Associated Vector) #Code: 536

Sensitization of Neuropathic Pain #Code: 535

Sensitization of Neuropathic Pain #Code: 535

Effect of Chronic Nerve Injury #Code: 534

Effect of Chronic Nerve Injury #Code: 534

Neuropathology of Neuropathic Pain #Code: 533

Neuropathology of Neuropathic Pain #Code: 533

Role of Carbohydrates in Immune cells, Blood vessels, and Intestine endothelium #Code: 532

Role of Carbohydrates in Immune cells, Blood vessels, and Intestine endothelium #Code: 532

N-Glycosylation alteration in B-cells (adaptive immune cells) during chronic inflammation #Code: 531

N-Glycosylation alteration in B-cells (adaptive immune cells) during chronic inflammation #Code: 531

N-Glycosylation alteration in T-cells (adaptive immune cells) during chronic inflammation #Code: 530

N-Glycosylation alteration in T-cells (adaptive immune cells) during chronic inflammation #Code: 530

N-Glycosylation alteration in innate immune cells during chronic inflammation #Code: 529

N-Glycosylation alteration in innate immune cells during chronic inflammation #Code: 529

Immune Response to Harmful Stimuli #Code: 528

Immune Response to Harmful Stimuli #Code: 528

Glycan binding proteins (GBP): Specificity and Location #Code: 527

Glycan binding proteins (GBP): Specificity and Location #Code: 527

Matrix Rigidity (ECM) related mechanobiological studies #Code: 526

Matrix Rigidity (ECM) related mechanobiological studies #Code: 526

Adeno Associated Virus (AAV) Transduction #Code: 525

Adeno Associated Virus (AAV) Transduction #Code: 525